Literature DB >> 22609744

Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells.

Min Xu1, Na Lu, Zhongying Sun, Haiwei Zhang, Qinsheng Dai, Libin Wei, Zhiyu Li, Qidong You, Qinglong Guo.   

Abstract

Hepatocellular carcinoma (HCC) is a refractory malignancy with a high incidence and large mortality. Current strategy for the chemotherapy of HCC focuses on developing agents with better efficacy and lower toxicity. In this study, we demonstrated that the natural flavonoid oroxylin A preferentially inhibited the viability of HCC cell line HepG2 but not the normal hepatic cell line L02. In HepG2 but not L02 cells, oroxylin A induced substantial production of intracellular H₂O₂ and inordinate activation of the PERK-eIF2α-ATF4-CHOP branch of the unfolded protein response (UPR) pathway, which resulted in the induction of TRB3 and causal reduction of p-AKT1/2/3 (Ser473). Moreover, these effects were eliminated by either the stable knockdown of CHOP or the pretreatment and then co-incubation with the specific H₂O₂ scavenger catalase. These results indicated that the H₂O₂-triggered overactivation of the UPR pathway and causal inactivation of AKT signaling contributed to the preferential cytotoxicity of oroxylin A in malignant HepG2 cells. Therefore, present study proposed an underlying molecular mechanism that implicated the selective antitumor effect of oroxylin A and recommended oroxylin A as a prospect for improving the current chemotherapeutic strategy for the treatment of HCC.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609744     DOI: 10.1016/j.toxlet.2012.05.008

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  12 in total

1.  Antidepressant-like activity of oroxylin A in mice models of depression: A behavioral and neurobiological characterization.

Authors:  Zhong-Hua Wu; Hua Fan; Shang-Yan Gao; Yan-Fei Jin; Bo Jiang; Jian Shen
Journal:  Front Pharmacol       Date:  2022-07-26       Impact factor: 5.988

Review 2.  The unfolded protein response in fatty liver disease.

Authors:  Anne Henkel; Richard M Green
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

3.  Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization.

Authors:  L Wei; Y Zhou; C Qiao; T Ni; Z Li; Q You; Q Guo; N Lu
Journal:  Cell Death Dis       Date:  2015-04-09       Impact factor: 8.469

Review 4.  Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

Authors:  Chen-Yi Liao; Ching-Chang Lee; Chi-chang Tsai; Chao-Wen Hsueh; Chih-Chiang Wang; I-Hung Chen; Ming-Kai Tsai; Mei-Yu Liu; An-Tie Hsieh; Kuan-Jen Su; Hau-Ming Wu; Shih-Chung Huang; Yi-Chen Wang; Chien-Yao Wang; Shu-Fang Huang; Yen-Cheng Yeh; Ren-Jy Ben; Shang-Tao Chien; Chin-Wen Hsu; Wu-Hsien Kuo
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

5.  Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition.

Authors:  Zhizhou Huang; Xueqiong Zhou; Yangfan He; Xiangyu Ke; Ying Wen; Fei Zou; Xuemei Chen
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

6.  Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism.

Authors:  Ting Ni; Zihao He; Yuanyuan Dai; Jingyue Yao; Qinglong Guo; Libin Wei
Journal:  Cell Death Dis       Date:  2017-06-08       Impact factor: 8.469

Review 7.  The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases.

Authors:  Sha Li; Hor Yue Tan; Ning Wang; Fan Cheung; Ming Hong; Yibin Feng
Journal:  Oxid Med Cell Longev       Date:  2018-02-04       Impact factor: 6.543

8.  Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Authors:  Jing-Yue Yao; Shu Xu; Yue-Ning Sun; Ye Xu; Qing-Long Guo; Li-Bin Wei
Journal:  Acta Pharmacol Sin       Date:  2021-06-29       Impact factor: 6.150

9.  Antiviral Activity of Oroxylin A against Coxsackievirus B3 Alleviates Virus-Induced Acute Pancreatic Damage in Mice.

Authors:  Bo-Eun Kwon; Jae-Hyoung Song; Hyuk-Hwan Song; Ju Won Kang; Sam Noh Hwang; Ki-Jong Rhee; Aeri Shim; Eun-Hye Hong; Yeon-Jeong Kim; Sang-Min Jeon; Sun-Young Chang; Dong-Eun Kim; Sungchan Cho; Hyun-Jeong Ko
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

10.  Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.

Authors:  Libin Wei; Yuanyuan Dai; Yuxin Zhou; Zihao He; Jingyue Yao; Li Zhao; Qinglong Guo; Lin Yang
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.